CVI Holdings’s Precision BioSciences DTIL Stock Holding History

CVI Holdings’s Portfolio DTIL Stock Details DTIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-141,716	Closed	-$6.8M	–	880
2022 Q2	$6.8M	Buy	+141,716	New	+$8.32M	0.49%	35

Other funds holding DTIL

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

CVI Holdings's DTIL Position: Q3 2022 in Review

CVI Holdings sold out of Precision BioSciences (DTIL) in Q3 2022, closing a stake of 141,716 shares — an estimated $6.8M sold.

CVI Holdings first reported a position in DTIL in Q2 2022 and held it in 1 quarter. The position peaked at $6.8M in Q2 2022. 102 funds tracked by Wall St. Rank hold DTIL as of Q3 2022.

CVI Holdings reported no remaining Precision BioSciences position as of Q3 2022 after selling out during the quarter.
CVI Holdings sold 141,716 Precision BioSciences shares in Q3 2022, an estimated $6.8M.
CVI Holdings first reported a position in Precision BioSciences in Q2 2022 and held it in 1 quarter.
CVI Holdings's Precision BioSciences position peaked at $6.8M in Q2 2022.
102 funds tracked by Wall St. Rank held Precision BioSciences as of Q3 2022.

Based on CVI Holdings's 13F filing for Q3 2022, filed 14 Nov 2022.